SBIO
ALPS Medical Breakthroughs ETF
ALPS Medical Breakthroughs ETF is an exchange-traded fund incorporated in the USA. The ETF seeks investment results that correspond generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs Index (ticker symbol: PMBI).
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 135.3 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Dec 30, 2014 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| KYMERA THERAPEUTICS, INC. | 4.2 % |
| CG ONCOLOGY, INC. | 3.6 % |
| MIRUM PHARMACEUTICALS, INC. | 3.6 % |
| CELCUITY INC. | 3.3 % |
| ALKERMES PLC | 3.3 % |
| XENON PHARMACEUTICALS, INC. | 3.0 % |
| AMICUS THERAPEUTICS INC | 3.0 % |
| APOGEE THERAPEUTICS, INC. | 2.9 % |
| VIKING THERAPEUTICS, INC. | 2.5 % |
| SPYRE THERAPEUTICS INC | 2.5 % |
Constituent Breakdown
| Number of holdings | 78 |
| Herfindahl-Hirschman Index | 189 |
| Wgt avg mkt cap (mns) | $2,223 |
| Large cap (>$10bn) | 48.8% |
| Mid cap ($2-10bn) | 35.9% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 89.5% |
| Emerging mkts. | 1.5% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 82.2 % |
 |
IRELAND | 3.3 % |
 |
CHINA | 1.3 % |
 |
BELGIUM | 1.3 % |
 |
BRITAIN | 1.0 % |
 |
GERMANY | 0.8 % |
 |
SWITZERLAND | 0.8 % |
 |
CAYMAN ISLANDS | 0.5 % |
Historical Performance
Standardized Performance (as of 02/28/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 0.7% | 64.6% | 18.0% | 19.4% | -1.3% | 9.4% | -- | 6.8% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.5% | -- | 0.5% |
| Total Returns | 0.7% | 64.6% | 18.0% | 19.5% | -1.3% | 9.9% | -- | 7.2% | Ann. Volatility | 31.6% | 32.1% | 30.6% | 30.2% | 33.9% | 33.5% | -- | 34.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.88 | 28% |
| MSCI EAFE | 0.96 | 24% |
| MSCI Emg Mkts | 0.78 | 19% |
Liquidity Measures
| Avg. volume (000) | 27 |
| ADV traded (mns) | $1 |
| Turnover | 1.1% |
| Avg. Bid/Ask (% of price) | 0.36% |
Technical Indicators
| 30d moving avg. (EMA) | $50.12 |
| Relative strength (RSI) | 46 |
| MACD/Signal | -0.55/-0.45 |
| Bollinger Bands (Upper/Lower) | $52.05/$47.83 |
| Short interest (% of AUM) | 1.3% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. SBIO |
Expenses vs. SBIO |
ALTAR Score™ vs. SBIO |
|---|---|---|---|---|
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 28.8% | +29 bp | 0.0% |
| XBI | State Street SPDR S&P Biotech ETF | 27.8% | -15 bp | +0.2% |
| BBP | Virtus LifeSci Biotech Products ETF | 22.2% | +29 bp | -3.8% |
| IBRN | iShares Neuroscience and Healthcare ETF | 14.8% | -3 bp | 0.0% |
| CANC | Tema Oncology ETF | 14.5% | +25 bp | -2.0% |
| LFSC | F/m Emerald Life Sciences Innovation ETF | 11.4% | +29 bp | 0.0% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 10.4% | +10 bp | -1.3% |
Risk and Returns: SBIO vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/3/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.0%
ALTAR SCORE™
PERCENTILE
AVOID
ETFRC RATING
There are 1,196 funds in the US Equity category with an average
ALTAR Score™ of 5.7% and a standard deviation
of 2.1%. SBIO's ALTAR Score™ is approximately 0.0 standard
deviations above the category average. This places SBIO in the percentile
among funds in the category.
Sell-Side Consensus
$72.11
PRICE TARGET
+34.8%
UPSIDE